Role of weekly paclitaxel in the treatment of advanced ovarian cancer
- 10 December 2002
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 44, 43-51
- https://doi.org/10.1016/s1040-8428(02)00103-8
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.International Journal of Gynecologic Cancer, 2001
- Remarks and conclusions on ovarian cancer treatment.International Journal of Gynecologic Cancer, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Up date in the management of advanced ovarian carcinomaCritical Reviews in Oncology/Hematology, 1999
- Paclitaxel (Taxol): An Inhibitor of Angiogenesis in a Highly Vascularized Transgenic Breast CancerCancer Biotherapy & Radiopharmaceuticals, 1999
- Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.Journal of Clinical Oncology, 1998
- Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.Journal of Clinical Oncology, 1998
- Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancerEuropean Journal Of Cancer, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Cisplatin nephrotoxicityCancer Chemotherapy and Pharmacology, 1989